Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Centre Hospitalier Universitaire De Nantes

Université De Nantes

Nantes Université

Université De Picardie Jules Verne

Université Lille 1 - Sciences Et Technologies

Université D'auvergne

Université D'auvergne Clermont 1

Inserm

David Deniaud

Mathieu Mevel

Eduard Ayuso

Adeline Sivignon

Sebastien Gouin

Julie Bouckaert

Tetiana Dumych

Rostyslav Bilyy

Arlette Darfeuille-Michaud

Sébastien Gouin

Aurélien Leray

The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.

RAAV with chemically modified capsid

The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a &#x2014;CSNH&#x2014; bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.

rAAV with chemically modified capsid

The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treatinginfections. Exemplary compounds are: 

Multimeric mannosides, a process for preparing the same and their uses as a drug

Growing community of inventors

Nantes, France

David Deniaud